Holen Sie sich die Stockscreener-App
11.75
3.37%
-0.41
Schlusskurs vom Vortag:
$12.16
Offen:
$12.33
24-Stunden-Volumen:
2.97M
Relative Volume:
0.75
Marktkapitalisierung:
$1.65B
Einnahmen:
$67.67M
Nettoeinkommen (Verlust:
$-412.69M
KGV:
-3.0706
EPS:
-3.8266
Netto-Cashflow:
$-395.87M
1W Leistung:
-3.21%
1M Leistung:
-13.03%
6M Leistung:
-11.39%
1J Leistung:
-29.26%
1-Tages-Spanne:
$11.66
$12.33
1-Wochen-Bereich:
$11.62
$12.97
52-Wochen-Spanne:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.75 | 1.65B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - stocktwits.com
Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative
Does Priority Review Change The Bull Case For Intellia Therapeutics Stock (NTLA)? - simplywall.st
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Eastern Progress
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: A Look At Its 95.76% Potential Upside - directorstalkinterviews.com
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - Investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on FDA priority review - Investing.com
Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria
Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView
Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci
Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com
Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Australia
NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus
Why is Intellia Therapeutics stock rallying today? - Investing.com
Intellia stock rises on FDA priority review (NTLA:NASDAQ) - Seeking Alpha
NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z Review - GuruFocus
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance
Intellia Therapeutics stock jumps on FDA priority review - Investing.com
If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEONARD JOHN M | President and CEO |
Aug 21 '26 |
Sale |
13.00 |
2,785 |
36,205 |
1,147,064 |
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):